- Home
- GLRE vs PRTA Comparison
GLRE vs PRTA Comparison
Compare GLRE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- PRTA
- Stock Information
- Founded
- GLRE 2004
- PRTA 2012
- Country
- GLRE Cayman Islands
- PRTA Ireland
- Employees
- GLRE N/A
- PRTA N/A
- Industry
- GLRE Property-Casualty Insurers
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- GLRE Finance
- PRTA Health Care
- Exchange
- GLRE Nasdaq
- PRTA Nasdaq
- Market Cap
- GLRE 439.8M
- PRTA 472.1M
- IPO Year
- GLRE 2007
- PRTA N/A
- Fundamental
- Price
- GLRE $12.93
- PRTA $10.31
- Analyst Decision
- GLRE
- PRTA Buy
- Analyst Count
- GLRE 0
- PRTA 9
- Target Price
- GLRE N/A
- PRTA $17.71
- AVG Volume (30 Days)
- GLRE 127.7K
- PRTA 567.4K
- Earning Date
- GLRE 11-03-2025
- PRTA 11-06-2025
- Dividend Yield
- GLRE N/A
- PRTA N/A
- EPS Growth
- GLRE N/A
- PRTA N/A
- EPS
- GLRE N/A
- PRTA N/A
- Revenue
- GLRE $661,540,000.00
- PRTA $11,786,000.00
- Revenue This Year
- GLRE N/A
- PRTA N/A
- Revenue Next Year
- GLRE N/A
- PRTA $672.02
- P/E Ratio
- GLRE N/A
- PRTA N/A
- Revenue Growth
- GLRE N/A
- PRTA N/A
- 52 Week Low
- GLRE $11.57
- PRTA $4.32
- 52 Week High
- GLRE $15.38
- PRTA $17.66
- Technical
- Relative Strength Index (RSI)
- GLRE 56.99
- PRTA 53.10
- Support Level
- GLRE $11.57
- PRTA $9.75
- Resistance Level
- GLRE $13.35
- PRTA $10.90
- Average True Range (ATR)
- GLRE 0.34
- PRTA 0.58
- MACD
- GLRE 0.08
- PRTA -0.07
- Stochastic Oscillator
- GLRE 79.83
- PRTA 45.86
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.